



HOUSE BILL 330: Controlled Substances Act - Updates.

2025-2026 General Assembly

Committee:	House Judiciary 2. If favorable, re-refer to Rules, Calendar, and Operations of the House	Date:	March 18, 2025
Introduced by:	Reps. Huneycutt, Miller, Pyrtle, Rhyne	Prepared by:	Hannah Kendrick
Analysis of:	First Edition		Susan Sitze Staff Attorney

OVERVIEW: *House Bill 330 would update the Controlled Substances Act to reflect developments in forensic chemistry.*

CURRENT LAW:

G.S. 90-89 governs Schedule I controlled substances. Schedule I substances are defined as having no accepted medical use, a high probability of abuse, or a lack of accepted safety for use in treatment under medical supervision.

BILL ANALYSIS:

House Bill 330 would make various changes to the classifications of Schedule I substances.

Section 1.(a) would expand the opioid classification to include 39 additional compounds.

Section 1.(b) would rename certain fentanyl derivatives under G.S. 90-89(1a).

Section 1.(c) would add nitazene compounds as a Schedule I controlled substance including any of the specified derivatives, their salts, isomers, or salts of isomers, unless specifically utilized in one of the following ways:

- As part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption.
- As a prescription administered under medical supervision.
- For research at a recognized institution.

Section 1.(d) would modify the chemical designation for the listed hallucinogenic substance.

Section 1.(e) would classify bromazolam as a systemic depressant.

Section 1.(f) would classify cycloalkyl as a substituted cathinones considered a stimulant.

Section 1.(g) would add oxindoles, indole acetamides, indazole acetaldehydes, and pyrazoles to the list of synthetic cannabinoids.

Section 1.(h), Section 1.(i), and Section 1.(j) would rename certain listed substances.

EFFECTIVE DATE: This act would become effective when it becomes law.

Kara McCraw
Director



Legislative Analysis
Division
919-733-2578